- Home
- Products
- Customized ADCs
- GPC3
- Anti-GPC3 (Codrituzumab)-MC-MMAF ADC
Anti-GPC3 (Codrituzumab)-MC-MMAF ADC (CAT#: ADC-W-2320)
This ADC product is comprised of an anti-GPC3 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- GPC3
- Alternative Names
- GPC3; glypican 3; SDYS; glypican-3; DGSX; glypican proteoglycan 3; OCI 5; SGB; SGBS; SGBS1; secreted glypican-3; intestinal protein OCI-5; heparan sulphate proteoglycan; MXR7; OCI-5; GTR2-2;
- Target Entrez Gene ID
- 2719
- Target UniProt ID
- P51654
- Overview
- Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
- Overview
- Humanized Anti-GPC3 IgG1-kappa antibody, Codrituzumab
- Generic name
- Codrituzumab
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ITGA2B (Abciximab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1464)
- Anti-IFNG (Crenezumab)-SPDB-DM4 ADC (CAT#: ADC-W-1227)
- Anti-TNFRSF8 (Iratumumab)-MC-MMAF ADC (CAT#: ADC-W-1888)
- Anti-CD70 (clone h1F6)-VC-AFP ADC (CAT#: ADC-W-365)
- Anti-IL6 (Elsilimomab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1439)
- Anti-IGF1R (Robatumumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1253)
- Anti-NOTCH1 (Brontictuzumab)-MC-MMAF ADC (CAT#: ADC-W-2362)
- Anti-ERBB3 (Duligotumab)-SMCC-DM1 ADC (CAT#: ADC-W-2240)
- Anti-ERBB2-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-607)
- Anti-SLC3A2 (clone IGNX)-DBM-MMAF ADC (CAT#: ADC-W-548)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2320. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2318 | Anti-GPC3 (Codrituzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2319 | Anti-GPC3 (Codrituzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2323 | Anti-GPC3 (Codrituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2322 | Anti-GPC3 (Codrituzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2321 | Anti-GPC3 (Codrituzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-485 | Anti-EphA2 (clone 1C1)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-517 | Anti-TM4SF1 ( clone v1.10)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
